Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs

详细信息    查看全文

• 作者：Vikas Tyagi^a ; Hanan Alwaseem^a ; Kristen M. O&rsquo ; Dwyer^b ; Jessica Ponder^c ; ^d ; Qi Ying Li^a ; Craig T. Jordan^c ; Rudi Fasan^a ; ^{rfasan@ur.rochester.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：PTL ; parthenolide ; AML ; acute myeloid leukemia ; LCS ; leukemia stem cells ; DMAPT ; dimethylamino-parthenolide ; PTDH ; phosphite dehydrogenase ; NADPH ; nicotinamide adenine dinucleotide phosphate (reduced) ; IPTG ; β-d-1-thiogalactopyranoside ; δ-ALA ; δ-aminolevulinic acid ; TB ; terrific broth ; DMSO ; dimethylsulfoxide ; DMAP ; 4-dimethylamino-pyridine ; EDA ; ethyl 2-diazo-acetate
• 刊名：Bioorganic & Medicinal Chemistry
• 出版年：2016
• 出版时间：1 September 2016
• 年：2016
• 卷：24
• 期：17
• 页码：3876-3886
• 全文大小：776 K

文摘

Parthenolide is a naturally occurring terpene with promising anticancer properties, particularly in the context of acute myeloid leukemia (AML). Optimization of this natural product has been challenged by limited opportunities for the late-stage functionalization of this molecule without affecting the pharmacologically important α-methylene-γ-lactone moiety. Here, we report the further development and application of a chemoenzymatic strategy to afford a series of new analogs of parthenolide functionalized at the aliphatic positions C9 and C14. Several of these compounds were determined to be able to kill leukemia cells and patient-derived primary AML specimens with improved activity compared to parthenolide, exhibiting LC₅₀ values in the low micromolar range. These studies demonstrate that different O–H functionalization chemistries can be applied to elaborate the parthenolide scaffold and that modifications at the C9 or C14 position can effectively enhance the antileukemic properties of this natural product. The C9-functionalized analogs 22a and 25b were identified as the most interesting compounds in terms of antileukemic potency and selectivity toward AML versus healthy blood cells.